Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cequent brings in $9mm through Series A round

Executive Summary

Cequent Pharmaceuticals (RNAi-based therapeutics for inflammatory diseases and cancer) raised $9mm through its Series A venture round. Novartis Option Fund was the lead participant; the investment was made in conjunction with Novartis's concurrent in-licensing of an option to Cequent's inflammatory bowel disease drug program. Other participants were Ampersand Ventures, Nexus Medical Partners, and Pappas Ventures.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies